Notice2025-06576
Prospective Grant of Exclusive License, Inter-Institutional Agreement-Institution Lead: Conductive Polymer Coated Electrodes for Dielectrophoretic Cell Positioning and Electroporation
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
April 17, 2025
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Abstract
The National Institute of Allergy and Infectious Diseases, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive, sublicensable patent license to Cambridge Enterprise Limited, University of Cambridge, located in Cambridge, United Kingdom, to practice the inventions embodied in the patent applications listed in the Supplementary Information section of this notice.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 73 (Thursday, April 17, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 73 (Thursday, April 17, 2025)]
[Notices]
[Pages 16137-16138]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-06576]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive License, Inter-Institutional
Agreement-Institution Lead: Conductive Polymer Coated Electrodes for
Dielectrophoretic Cell Positioning and Electroporation
AGENCY: National Institutes of Health, National Institute of Allergy
and Infectious Diseases.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The National Institute of Allergy and Infectious Diseases, an
institute of the National Institutes of Health, Department of Health
and Human Services, is contemplating the grant of an exclusive,
sublicensable patent license to Cambridge Enterprise Limited,
University of Cambridge, located in Cambridge, United Kingdom, to
practice the inventions embodied in the patent applications listed in
the Supplementary Information section of this notice.
DATES: Only written comments and/or applications for a license which
are received by the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases on or
before May 2, 2025 will be considered.
ADDRESSES: Requests for copies of the patent applications, inquiries,
and comments relating to the contemplated exclusive patent license
should be directed to: Wade Green, Ph.D., Acting Branch Chief,
Technology Transfer and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Suite
2G, MSC9804, Rockville, MD 20852-9804, phone number 301-761-7505, or
<a href="/cdn-cgi/l/email-protection#9ee9fffafbb0f9ecfbfbf0def0f7f6b0f9f1e8"><span class="__cf_email__" data-cfemail="8dfaece9e8a3eaffe8e8e3cde3e4e5a3eae2fb">[email protected]</span></a>.
SUPPLEMENTARY INFORMATION: The following represents the intellectual
property to be licensed under the prospective agreement: European
Patent Application Patent Application No. EP23386021.2, filed March 10,
2023, titled ``Conductive Polymer Coated Electrodes for
Dielectrophoretic Cell Positioning and Electroporation'' (HHS Reference
No. E-266-2023-0-EP-01) and International Patent Application No. PCT/
EP2024/056247, filed on March 8, 2024, titled ``Conductive Polymer
Coated Electrodes for Dielectrophoretic Cell Positioning and
Electroporation'' (HHS Reference No. E-266-2023-0-PC-01). All rights in
these inventions have been assigned to Cambridge Enterprise Limited and
the Government of the United States of America.
The prospective patent license will be for the purpose of
consolidating patent rights with Cambridge Enterprise Limited, the co-
owner of said rights, for commercial development and marketing.
Consolidation of these co-owned rights is intended to expedite
development of the invention, consistent with the goals of the Bayh-
Dole Act codified as 35 U.S.C. 200-212.
The prospective patent license will be exclusive, and may be
limited to those fields of use commensurate in scope with the patent
rights. It will be sublicensable, and any sublicenses granted by
Cambridge Enterprise Limited in the United Kingdom will be subject to
the provisions of 37 CFR part 404.
The subject patent rights pertain to devices and methods for
single-cell electroporation of human cells for clinical uses.
Specifically, this subject invention describes certain conductive
polymer electrodes that have properties that may allow for their use in
the development of microfluidic-based electroporation devices for
clinical uses.
[[Page 16138]]
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive license will be royalty-bearing,
and may be granted unless within fifteen (15) days from the date of
this published notice, the National Insitute of Allergy and Infectious
Diseases receives written evidence and argument that establishes that
the grant of the license would not be consistent with the requirements
of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or
objections. Comments and objections, other than those in the form of a
license application, will not be treated confidentially, and may be
made publicly available.
License applications submitted in response to this Notice will be
presumed to contain business confidential information and any release
of information in these license applications will be made only as
required and upon a request under the Freedom of Information Act, 5
U.S.C. 552.
Dated: April 14, 2025
Surekha Vathyam,
Director, Technology Transfer and Intellectual Property Office,
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2025-06576 Filed 4-16-25; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on April 17, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.